Literature DB >> 14617205

Crossing the bridge: large animal models in translational transplantation research.

Allan D Kirk1.   

Abstract

Many methods for reducing the immunosuppressive requirements of allotransplantation have been proposed based on a growing understanding of physiological and allospecific immunity. As these regimens are developed for clinical application, they require validation in models that are reasonably predictive of their performance in humans. This article provides an overview of the large animal models commonly used to test immunomodulatory organ transplant protocols. The rationale for the use of large animals and the effects of common immunosuppressants in the dog, pig, and non-human primate are reviewed. Promising methods for the induction of allospecific tolerance are surveyed with references to early human trials where appropriate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617205     DOI: 10.1046/j.1600-065x.2003.00081.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  47 in total

1.  Significant mobilization of both conventional and regulatory T cells with AMD3100.

Authors:  Leslie S Kean; Sharon Sen; Olusegun Onabajo; Karnail Singh; Jennifer Robertson; Linda Stempora; Aylin C Bonifacino; Mark E Metzger; Daniel E L Promislow; Joseph J Mattapallil; Robert E Donahue
Journal:  Blood       Date:  2011-10-11       Impact factor: 22.113

Review 2.  B cells and transplantation tolerance.

Authors:  Allan D Kirk; Nicole A Turgeon; Neal N Iwakoshi
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

3.  Unexplained post-renal transplant tolerance: a case report.

Authors:  Sailaja Kesiraju; Uma Maheswara Rao Ch; Purna Paritala; Sreedhar Reddy; V S Reddy; S Sahariah
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

4.  A modified heterotopic swine hind limb transplant model for translational vascularized composite allotransplantation (VCA) research.

Authors:  Zuhaib Ibrahim; Damon S Cooney; Jaimie T Shores; Justin M Sacks; Eric G Wimmers; Steven C Bonawitz; Chad Gordon; Dawn Ruben; Stefan Schneeberger; W P Andrew Lee; Gerald Brandacher
Journal:  J Vis Exp       Date:  2013-10-14       Impact factor: 1.355

5.  A human-specific mutation limits nonhuman primate efficacy in preclinical xenotransplantation studies.

Authors:  Joshua P Waldman; Linda G Brock; Michael A Rees
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

Review 6.  Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation.

Authors:  Zachary Fitch; Robin Schmitz; Jean Kwun; Bernhard Hering; Joren Madsen; Stuart J Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2019-04-05       Impact factor: 3.943

Review 7.  Viewing transplantation immunology through today's lens: new models, new imaging, and new insights.

Authors:  Alex Y Huang; W Nicholas Haining; Deborah S Barkauskas; Jay T Myers; Agne Petrosiute; Aneesah P Garrett; Karnail Singh; Kenneth R Cooke; Leslie S Kean
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-22       Impact factor: 5.742

8.  Sarcolemmal Complement Membrane Attack Complex Deposits During Acute Rejection of Myofibers in Nonhuman Primates.

Authors:  Daniel Skuk; Jacques P Tremblay
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

9.  Pathogen Stimulation History Impacts Donor-Specific CD8(+) T Cell Susceptibility to Costimulation/Integrin Blockade-Based Therapy.

Authors:  I R Badell; W H Kitchens; M E Wagener; A E Lukacher; C P Larsen; M L Ford
Journal:  Am J Transplant       Date:  2015-07-30       Impact factor: 8.086

10.  Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.

Authors:  Tim A Weaver; Ali H Charafeddine; Avinash Agarwal; Alexandra P Turner; Maria Russell; Frank V Leopardi; Robert L Kampen; Linda Stempora; Mingqing Song; Christian P Larsen; Allan D Kirk
Journal:  Nat Med       Date:  2009-07-05       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.